Milestone Pharmaceuticals Inc. Increase (Decrease) in Accounts Payable and Accrued Liabilities
Milestone Pharmaceuticals Inc. (MIST) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $4.43 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-20.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-03-20
- Milestone Pharmaceuticals Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was $1.95M, a 32.41% decline year-over-year.
- Milestone Pharmaceuticals Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $1.27M, a 88.31% increase year-over-year.
- Milestone Pharmaceuticals Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-06-30 was -$3.65M, a 585.77% decline year-over-year.
- Milestone Pharmaceuticals Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-03-31 was $4.87M.
- Milestone Pharmaceuticals Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was $4.43M, a 406.51% increase from fiscal 2024.
- Milestone Pharmaceuticals Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was $875.00K, a 15.54% decline from fiscal 2023.
- Milestone Pharmaceuticals Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was $1.04M.
- Milestone Pharmaceuticals Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was -$907.00K, a 242.39% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2025-12-31 | $1.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-20 | $3.22M derived: sum of 2 quarters · filed 2026-03-20 | -$434.00K derived: sum of 3 quarters · filed 2026-03-20 | $4.43M 10-K · filed 2026-03-20 |
| 2025-09-30 | $1.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$2.38M derived: sum of 2 quarters · filed 2025-11-12 | $2.49M 10-Q · filed 2025-11-12 | $5.37M derived: sum of 4 quarters · filed 2026-03-20 |
| 2025-06-30 | -$3.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $1.21M 10-Q · filed 2025-08-12 | $4.09M derived: sum of 3 quarters · filed 2026-03-20 | $4.77M derived: sum of 4 quarters · filed 2026-03-20 |
| 2025-03-31 | $4.87M 10-Q · filed 2025-05-14 | $7.75M derived: sum of 2 quarters · filed 2026-03-20 | $8.42M derived: sum of 3 quarters · filed 2026-03-20 | $9.17M derived: sum of 4 quarters · filed 2026-03-20 |
| 2024-12-31 | $2.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-20 | $3.56M derived: sum of 2 quarters · filed 2026-03-20 | $4.31M derived: sum of 3 quarters · filed 2026-03-20 | $875.00K 10-K · filed 2026-03-20 |
| 2024-09-30 | $676.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $1.43M derived: sum of 2 quarters · filed 2025-11-12 | -$2.00M 10-Q · filed 2025-11-12 | -$2.91M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $752.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$2.68M 10-Q · filed 2025-08-12 | -$3.58M derived: sum of 3 quarters · filed 2025-08-12 | -$2.29M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$3.43M 10-Q · filed 2025-05-14 | -$4.34M derived: sum of 2 quarters · filed 2025-05-14 | -$3.04M derived: sum of 3 quarters · filed 2025-05-14 | -$1.48M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$904.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $393.00K derived: sum of 2 quarters · filed 2025-03-13 | $1.95M derived: sum of 3 quarters · filed 2025-03-13 | $1.04M 10-K · filed 2025-03-13 |
| 2023-09-30 | $1.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $2.85M derived: sum of 2 quarters · filed 2024-11-12 | $1.94M 10-Q · filed 2024-11-12 | $1.55M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $1.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $643.00K 10-Q · filed 2024-08-08 | $252.00K derived: sum of 3 quarters · filed 2024-08-08 | $2.20M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$912.00K 10-Q · filed 2024-05-13 | -$1.30M derived: sum of 2 quarters · filed 2024-05-13 | $645.00K derived: sum of 3 quarters · filed 2024-05-13 | $320.00K derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | -$391.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $1.56M derived: sum of 2 quarters · filed 2024-03-21 | $1.23M derived: sum of 3 quarters · filed 2024-03-21 | -$907.00K 10-K · filed 2024-03-21 |
| 2022-09-30 | $1.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $1.62M derived: sum of 2 quarters · filed 2023-11-13 | -$516.00K 10-Q · filed 2023-11-13 | $442.00K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$325.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$2.46M 10-Q · filed 2023-08-10 | -$1.51M derived: sum of 3 quarters · filed 2023-08-10 | -$982.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$2.14M 10-Q · filed 2023-05-11 | -$1.18M derived: sum of 2 quarters · filed 2023-05-11 | -$657.00K derived: sum of 3 quarters · filed 2023-05-11 | -$1.15M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $958.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $1.48M derived: sum of 2 quarters · filed 2023-03-29 | $987.00K derived: sum of 3 quarters · filed 2023-03-29 | $637.00K 10-K · filed 2023-03-29 |
| 2021-09-30 | $524.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $29.00K derived: sum of 2 quarters · filed 2022-11-10 | -$321.00K 10-Q · filed 2022-11-10 | -$54.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$495.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | -$845.00K 10-Q · filed 2022-08-10 | -$578.00K derived: sum of 3 quarters · filed 2022-08-10 | $235.00K derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | -$350.00K 10-Q · filed 2022-05-12 | -$83.00K derived: sum of 2 quarters · filed 2022-05-12 | $730.00K derived: sum of 3 quarters · filed 2022-05-12 | $394.00K derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $267.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | $1.08M derived: sum of 2 quarters · filed 2022-03-24 | $744.00K derived: sum of 3 quarters · filed 2022-03-24 | -$2.08M 10-K · filed 2022-03-24 |
| 2020-09-30 | $813.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $477.00K derived: sum of 2 quarters · filed 2021-11-12 | -$2.35M 10-Q · filed 2021-11-12 | -$2.83M derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | -$336.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | -$3.16M 10-Q · filed 2021-08-11 | -$3.64M derived: sum of 3 quarters · filed 2021-08-11 | -$725.00K derived: sum of 4 quarters · filed 2021-08-11 |
| 2020-03-31 | -$2.83M 10-Q · filed 2021-05-17 | -$3.31M derived: sum of 2 quarters · filed 2021-05-17 | -$389.00K derived: sum of 3 quarters · filed 2021-05-17 | $1.26M derived: sum of 4 quarters · filed 2021-05-17 |
| 2019-12-31 | -$481.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | $2.44M derived: sum of 2 quarters · filed 2021-03-29 | $4.09M derived: sum of 3 quarters · filed 2021-03-29 | $3.52M 10-K · filed 2021-03-29 |
| 2019-09-30 | $2.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13 | $4.57M derived: sum of 2 quarters · filed 2020-11-13 | $4.00M 10-Q · filed 2020-11-13 | $6.25M derived: sum of 4 quarters · filed 2020-11-13 |
| 2019-06-30 | $1.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | $1.08M 10-Q · filed 2020-08-12 | $3.33M derived: sum of 3 quarters · filed 2020-10-23 | $4.37M derived: sum of 4 quarters · filed 2020-10-23 |
| 2019-03-31 | -$571.00K 10-Q · filed 2020-05-14 | $1.68M derived: sum of 2 quarters · filed 2020-10-23 | $2.72M derived: sum of 3 quarters · filed 2020-10-23 | $2.44M derived: sum of 4 quarters · filed 2020-10-23 |
| 2018-12-31 | $2.25M derived: 10-K/A 12 month − 10-Q 9 month · filed 2020-10-23 | $3.29M derived: sum of 2 quarters · filed 2020-10-23 | $3.01M derived: sum of 3 quarters · filed 2020-10-23 | $2.88M 10-K/A · filed 2020-10-23 |
| 2018-09-30 | $1.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | $759.00K derived: sum of 2 quarters · filed 2019-11-13 | $624.00K 10-Q · filed 2019-11-13 | |
| 2018-06-30 | -$280.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-13 | -$415.00K 10-Q · filed 2019-08-13 | ||
| 2018-03-31 | -$135.00K 10-Q · filed 2019-06-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B |